An increase in integrin-linked kinase noncanonically confers NF-κB-mediated growth advantages to gastric cancer cells by activating ERK1/2

Cell Communication and Signaling

Volumn 12, Issue 1, 2014, Pages

  Tseng, Po Chun ^a   Chen, Chia Ling ^b   Shan, Yan Shen ^a   Chang, Wen Teng ^c   Liu, Hsiao Sheng ^a   Hong, Tse Ming ^a   Hsieh, Chia Yuan ^a   Lin, Sheng Hsiang ^a   Lin, Chiou Feng ^a,d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cell growth; ERK1 2; ILK; IQGAP1; NK KB

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN LINKED KINASE; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; RAF PROTEIN; RAS PROTEIN; S6 KINASE; SHORT HAIRPIN RNA; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; INTEGRIN-LINKED KINASE; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STABILITY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UBIQUITINATION; UPREGULATION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; MALE; METABOLISM; STOMACH TUMOR; TUMOR CELL LINE; WOUND HEALING;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MALE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; RAS GTPASE-ACTIVATING PROTEINS; RAS PROTEINS; STOMACH NEOPLASMS; WOUND HEALING;

EID: 84964695261     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-014-0069-3     Document Type: Article

References (67)

1. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC, Dedhar S: Regulation of cell adhesion and anchoragedependent growth by a new beta 1-integrin-linked protein kinase. Nature 1996, 379:91-96.
2. Wu C, Dedhar S: Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 2001, 155:505-510.
3. Persad S, Dedhar S: The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev 2003, 22:375-384.
4. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S: Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A 1998, 95:11211-11216.
5. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P: Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 2010, 10:858-870.
6. McDonald PC, Fielding AB, Dedhar S: Integrin-linked kinase-essential roles in physiology and cancer biology. J Cell Sci 2008, 121:3121-3132.
7. Dobreva I, Fielding A, Foster LJ, Dedhar S: Mapping the integrin-linked kinase interactome using SILAC. J Proteome Res 2008, 7:1740-1749.
8. Morimoto AM, Tomlinson MG, Nakatani K, Bolen JB, Roth RA, Herbst R: The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase activity. Oncogene 2000, 19:200-209.
9. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP, Dedhar S: Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001, 276:27462-27469.
10. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998, 95:15587-15591.
11. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999, 96:4240-4245.
12. D'Amico M, Hulit J, Amanatullah DF, Zafonte BT, Albanese C, Bouzahzah B, Fu M, Augenlicht LH, Donehower LA, Takemaru K, Moon RT, Davis R, Lisanti MP, Shtutman M, Zhurinsky J, Ben-Ze'ev A, Troussard AA, Dedhar S, Pestell RG: The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 2000, 275:32649-32657.
13. Makino K, Day CP, Wang SC, Li YM, Hung MC: Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway. Oncogene 2004, 23:3883-3887.
14. Agouni A, Sourbier C, Danilin S, Rothhut S, Lindner V, Jacqmin D, Helwig JJ, Lang H, Massfelder T: Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B. Carcinogenesis 2007, 28:1893-1901.
15. Medici D, Nawshad A: Type I collagen promotes epithelial-mesenchymal transition through ILK-dependent activation of NF-kappaB and LEF-1. Matrix Biol 2010, 29:161-165.
16. Hashiramoto A, Murata M, Kawazoe T, Yoshida K, Akiyama C, Shiozawa K, Shiozawa S: Heat shock protein 90 maintains the tumour-like character of rheumatoid synovial cells by stabilizing integrin-linked kinase, extracellular signal-regulated kinase and protein kinase B. Rheumatology (Oxford) 2011, 50:852-861.
17. Wani AA, Jafarnejad SM, Zhou J, Li G: Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kappaB/interleukin-6 signaling pathway. Oncogene 2011, 30:2778-2788.
18. Liang CH, Chiu SY, Hsu IL, Wu YY, Tsai YT, Ke JY, Pan SH, Hsu YC, Li KC, Yang PC, Chen YL, Hong TM: alpha-Catulin drives metastasis by activating ILK and driving an alphavbeta3 integrin signaling axis. Cancer Res 2013, 73:428-438.
19. Zhao M, Gao Y, Wang L, Liu S, Han B, Ma L, Ling Y, Mao S, Wang X: Overexpression of integrin-linked kinase promotes lung cancer cell migration and invasion via NF-kappaB-mediated upregulation of matrix metalloproteinase-9. Int J Med Sci 2013, 10:995-1002.
20. Liang F, Zhang S, Wang B, Qiu J, Wang Y: Overexpression of integrin-linked kinase (ILK) promotes glioma cell invasion and migration and downregulates E-cadherin via the NF-kappaB pathway. J Mol Histol 2013, 45:141-151.
21. Zhang Y, Chen K, Tu Y, Wu C: Distinct roles of two structurally closely related focal adhesion proteins, alpha-parvins and beta-parvins, in regulation of cell morphology and survival. J Biol Chem 2004, 279:41695-41705.
22. Huang Y, Li J, Zhang Y, Wu C: The roles of integrin-linked kinase in the regulation of myogenic differentiation. J Cell Biol 2000, 150:861-872.
23. Noguchi S, Yasui Y, Iwasaki J, Kumazaki M, Yamada N, Naito S, Akao Y: Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett 2013, 328:353-361.
24. Dedhar S: Cell-substrate interactions and signaling through ILK. Curr Opin Cell Biol 2000, 12:250-256.
25. Aoyagi Y, Fujita N, Tsuruo T: Stabilization of integrin-linked kinase by binding to Hsp90. Biochem Biophys Res Commun 2005, 331:1061-1068.
26. Radovanac K, Morgner J, Schulz JN, Blumbach K, Patterson C, Geiger T, Mann M, Krieg T, Eckes B, Fassler R, Wickstrom SA: Stabilization of integrinlinked kinase by the Hsp90-CHIP axis impacts cellular force generation, migration and the fibrotic response. EMBO J 2013, 32:1409-1424.
27. Malumbres M, Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465.
28. Ito R, Oue N, Zhu X, Yoshida K, Nakayama H, Yokozaki H, Yasui W: Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma. Virchows Arch 2003, 442:118-123.
29. Graff JR, Deddens JA, Konicek BW, Colligan BM, Hurst BM, Carter HW, Carter JH: Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res 2001, 7:1987-1991.
30. Takanami I: Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 2005, 5:1.
31. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS: K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006, 8:30-38.
32. Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH: Infrequent RAS oncogene mutations in human prostate cancer. Prostate 1992, 20:327-338.
33. Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Tanaka S, Yoshihara M, Shimamoto F, Chayama K: K-ras mutation in helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. Int J Cancer 2002, 97:562-566.
34. Zhao G, Guo LL, Xu JY, Yang H, Huang MX, Xiao G: Integrin-linked kinase in gastric cancer cell attachment, invasion and tumor growth. World J Gastroenterol 2011, 17:3487-3496.
35. Soutto M, Belkhiri A, Piazuelo MB, Schneider BG, Peng D, Jiang A, Washington MK, Kokoye Y, Crowe SE, Zaika A, Crowe SE, Zaika A, Correa P, Peek RM Jr, El-Rifai W: Loss of TFF1 is associated with activation of NF-kappaB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest 2011, 121:1753-1767.
36. Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, Chen CS: Identification and characterization of a novel integrin-linked kinase inhibitor. J Med Chem 2011, 54:6364-6374.
37. Yoon YK, Kim HP, Han SW, Hur HS, Oh Do Y, Im SA, Bang YJ, Kim TY: Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 2009, 8:2526-2536.
38. Ravi R, Bedi A: NF-kappaB in cancer-a friend turned foe. Drug Resist Updat 2004, 7:53-67.
39. Roy M, Li Z, Sacks DB: IQGAP1 is a scaffold for mitogen-activated protein kinase signaling. Mol Cell Biol 2005, 25:7940-7952.
40. Jameson KL, Mazur PK, Zehnder AM, Zhang J, Zarnegar B, Sage J, Khavari PA: IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med 2013, 19:626-630.
41. Knoll R, Postel R, Wang J, Kratzner R, Hennecke G, Vacaru AM, Vakeel P, Schubert C, Murthy K, Rana BK, Kube D, Knöll G, Schäfer K, Hayashi T, Holm T, Kimura A, Schork N, Toliat MR, Nürnberg P, Schultheiss HP, Schaper W, Schaper J, Bos E, Den Hertog J, van Eeden FJ, Peters PJ, Hasenfuss G, Chien KR, Bakkers J: Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation 2007, 116:515-525.
42. Souma Y, Nishida T, Serada S, Iwahori K, Takahashi T, Fujimoto M, Ripley B, Nakajima K, Miyazaki Y, Mori M, Doki Y, Sawa Y, Naka T: Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells. Int J Cancer 2012, 131:1287-1296.
43. Tseng PC, Huang WC, Chen CL, Sheu BS, Shan YS, Tsai CC, Wang CY, Chen SO, Hsieh CY, Lin CF: Regulation of SHP2 by PTEN/AKT/GSK-3beta signaling facilitates IFN-gamma resistance in hyperproliferating gastric cancer. Immunobiology 2012, 217:926-934.
44. Emanuele MJ, Elia AE, Xu Q, Thoma CR, Izhar L, Leng Y, Guo A, Chen YN, Rush J, Hsu PW, Yen HC, Elledge SJ: Global identification of modular cullin-RING ligase substrates. Cell 2011, 147:459-474.
45. Murata S, Minami Y, Minami M, Chiba T, Tanaka K: CHIP is a chaperonedependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep 2001, 2:1133-1138.
46. Alberts SR, Cervantes A, van de Velde CJ: Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003, 14(Suppl 2):ii31-ii36.
47. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16.
48. Huang PH, Xu AM, White FM: Oncogenic EGFR signaling networks in glioma. Sci Signal 2009, 2:re6.
49. Meyer-ter-Vehn T, Covacci A, Kist M, Pahl HL: Helicobacter pylori activates mitogen-activated protein kinase cascades and induces expression of the proto-oncogenes c-fos and c-jun. J Biol Chem 2000, 275:16064-16072.
50. Nakayama M, Hisatsune J, Yamasaki E, Isomoto H, Kurazono H, Hatakeyama M, Azuma T, Yamaoka Y, Yahiro K, Moss J, Hirayama T: Helicobacter pylori VacA-induced inhibition of GSK3 through the PI3K/Akt signaling pathway. J Biol Chem 2009, 284:1612-1619.
51. Ramos JW: The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 2008, 40:2707-2719.
52. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME: Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000, 60:3081-3087.
53. White CD, Erdemir HH, Sacks DB: IQGAP1 and its binding proteins control diverse biological functions. Cell Signal 2012, 24:826-834.
54. Brill S, Li S, Lyman CW, Church DM, Wasmuth JJ, Weissbach L, Bernards A, Snijders AJ: The Ras GTPase-activating-protein-related human protein IQGAP2 harbors a potential actin binding domain and interacts with calmodulin and Rho family GTPases. Mol Cell Biol 1996, 16:4869-4878.
55. Hart MJ, Callow MG, Souza B, Polakis P: IQGAP1, a calmodulin-binding protein with a rasGAP-related domain, is a potential effector for cdc42Hs. EMBO J 1996, 15:2997-3005.
56. Wickstrom SA, Lange A, Hess MW, Polleux J, Spatz JP, Kruger M, Pfaller K, Lambacher A, Bloch W, Mann M, Huber LA, Fässler R: Integrin-linked kinase controls microtubule dynamics required for plasma membrane targeting of caveolae. Dev Cell 2010, 19:574-588.
57. Walch A, Seidl S, Hermannstadter C, Rauser S, Deplazes J, Langer R, von Weyhern CH, Sarbia M, Busch R, Feith M, Feith M, Gillen S, Höfler H, Luber B: Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer. Mod Pathol 2008, 21:544-552.
58. Takatsuki H, Komatsu S, Sano R, Takada Y, Tsuji T: Adhesion of gastric carcinoma cells to peritoneum mediated by alpha3beta1 integrin (VLA-3). Cancer Res 2004, 64:6065-6070.
59. Ke JJ, Shao QS, Ling ZQ: Expression of E-selectin, integrin beta1 and immunoglobulin superfamily member in human gastric carcinoma cells and its clinicopathologic significance. World J Gastroenterol 2006, 12:3609-3611.
60. King CC, Gardiner EM, Zenke FT, Bohl BP, Newton AC, Hemmings BA, Bokoch GM: p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1). J Biol Chem 2000, 275:41201-41209.
61. Acconcia F, Barnes CJ, Singh RR, Talukder AH, Kumar R: Phosphorylationdependent regulation of nuclear localization and functions of integrinlinked kinase. Proc Natl Acad Sci U S A 2007, 104:6782-6787.
62. Fujita N, Sato S, Ishida A, Tsuruo T: Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2002, 277:10346-10353.
63. Sato S, Fujita N, Tsuruo T: Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 2000, 97:10832-10837.
64. Schulte TW, Blagosklonny MV, Ingui C, Neckers L: Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem1995, 270:24585-24588.
65. Zuehlke A, Johnson JL: Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 2010, 93:211-217.
66. Dan L, Jian D, Na L, Xiaozhong W: Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901. Onco Targets Ther 2012, 5:271-277.
67. Erez N, Truitt M, Olson P, Arron ST, Hanahan D: Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell 2010, 17:135-147.